In HER2+ breast cancer, inhibition with lapatinib increases the expression of HER2 and improves the efficacy of immune system mediated cytotoxicity induced by the HER2-targeting antibody trastuzumab (Scaltriti et al., 2009). Here, ERBB2 is linked to breast carcinoma.